Bradley Corr, MD


Dr. Corr on the Utilization of Molecular Profiling in Endometrial Cancer

Bradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.

Larysa J. Sanchez, MD


Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple Myeloma

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

Michael R. Grunwald, MD, FACP


Dr. Grunwald on the Clinical Implications of Tisagenlecleucel in B-ALL Treatment

Michael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

Evan B. Shereck, MD, MEd


Dr. Shereck Highlights a Day In the Life of an Attending Physician

Evan B. Shereck, MD, MEd, serves as professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University. In this episode, she highlights the average work day as an attending physician.

John F. Lazar, MD


Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

IU School of Medicine


IU Cancer Researchers Refining Colorectal Cancer Classification, Identifying New Targets for Treatment Using Cutting-Edge, Single-Cell Technology

Analyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.

Peter Forsberg, MD


Advice for Community Oncologists Treating Patients With R/R MM

Drs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.

Daniel C. Danila, MD


Dr. Danila on Examining Immunotherapy in Early-Stage Prostate Cancer

Daniel C. Danila, MD, discusses ​the rationale for examining immunotherapy in early-stage prostate cancer.

Antonia DePace


From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI Cancer

Daniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.

Ruchi Bhatt, DO


Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.

Ismail Jatoi, MD


Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast Cancer

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

Irene Morae Kang, MD


Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast Cancer

Irene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.

Doug Smith, MD, John Hopkins Medicine


MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

Namrata (Neena) Vijayvergia, MD


Dr. Vijayvergia on the Efficacy of Pembrolizumab in MSI-H Advanced Gastric Cancer

Namrata (Neena) Vijayvergia, MD, discusses the efficacy of pembrolizumab with or without chemotherapy in patients with microsatellite instability–high advanced gastric cancer.

University of Cincinnati Cancer Center


Making Pancreatic Cancer Treatments More Effective

Pancreatic cancer diagnoses are increasing more rapidly than any other cancer type while remaining one of the most deadly cancers.

Michael Blackman, MD


Patient Experiences Can Affect a Practice’s Financial Health

The patient experience is a critical factor in the success of any healthcare practice, and its importance is increasing with the rise of health care consumerism.

Jose Javier Bravo-Cordero, MD


Dr. Bravo-Cordero on the Role of the Extracellular Matrix in Breast Cancer Dormancy

Jose Javier Bravo-Cordero, MD, discusses the role of extracellular matrix proteomics and disseminating tumor cells when regulating the tumor microenvironment to induce dormancy in breast cancer.

Evan Lipson, MD


Closing Remarks on the Treatment of Patients With Metastatic Melanoma

Experts share closing remarks and provide advice for clinicians treating patients with metastatic melanoma.

Ahmet Sezer, MD


Dr. Sezer on the FDA Approval of Cemiplimab in Frontline Advanced NSCLC With High PD-L1 Expression

Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, discusses the FDA approval of cemiplimab-rwlc (Libtayo) as frontline treatment for patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression.

Salvatore Siena, MD


Dr. Siena on the Rationale for the DESTINY-CRC01 in Metastatic CRC

Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Ulka Nitin Vaishampayan, MBBS


Dr. Vaishampayan on the PROBE Trial in Advanced RCC

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the phase 3 PROBE trial in advanced renal cell carcinoma.

Phillip Palmbos, MD, PhD


Dr. Palmbos on the Utilization of Nivolumab Following Cystectomy in Muscle-Invasive Bladder Cancer

Phillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer.

Sandip P. Patel, MD, UC San Diego Health


Second-Line Treatment of SCLC

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

Ignacio Duran, MD, PhD


Metastatic Urothelial Carcinoma: Unmet Needs and Future Directions

Expert reflection on the current unmet needs in metastatic urothelial carcinoma and hope for future improvements in the treatment armamentarium.

Mohammed M. Milhem, MBBS


Dr. Milhem on the Utility of RP1 in Solid Tumors

Mohammed Milhem, MBBS, MBBS, discusses the utility of vusolimogeneoderparepvec in solid tumors.

John Zalcberg, PhD, OAM


Dr. Zalcberg on the Rationale for Dose Escalation With Ripretinib in Advanced GIST

John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Ronda S. Henry-Tillman, MD


Comprehensive Treatment Advances Care for Patients With Early-Stage Breast Cancer

Advances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.

Pramit Khetrapal, MD


Dr. Khetrapal on Intracorporeal Robotic vs Open Cystectomy in MIBC

Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.

Toby Campbell, MD, MSCI


Palliative Care Builds Bridges in Oncology Practice

Toby Campbell, MD, MSCI, discusses the nuances of palliative care in oncology.